0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessPatients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous recombination repair gene alterations (HRR+), particularly BRCA1/2, benefit from first-line therapy with niraparib plus abiraterone acetate and prednisone (AAP). Here we report longer follow-up from the second prespecified interim analysis (IA2).
K.N. Chi, Shahneen Sandhu, Matthew R. Smith, Gerhardt Attard, Marniza Saad, David Olmos, Elena Castro, Guilhem Roubaud, Andrea Juliana Gomes, Eric J. Small, Dana E. Rathkopf, Howard Gurney, Wonho Jung, Gary Mason, Shiva Dibaj, Daphne Wu, B. Diorio, Karen A. Urtishak, A. del Corral, Peter Francis, W. Kim, Eleni Efstathiou (2023). Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. , 34(9), DOI: https://doi.org/10.1016/j.annonc.2023.06.009.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2023
Authors
22
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1016/j.annonc.2023.06.009
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
